$EMBC Fraud Notification: Embecta Sued for Securities Fraud
A class action lawsuit has been filed against Embecta Corp. (NASDAQ:EMBC) and its executives for securities fraud after its stock dropped over 57% following disappointing Q2 2026 results. The lawsuit alleges Embecta misled investors about the strength of its insulin pen needle product category, facing significant competition and market softness despite positive claims. Investors have until August 17, 2026, to seek lead plaintiff status.
Embecta Corp. Stock Drop - Robbins LLP Urges EMBC Investors to Contact the Firm for Information About the Class Action Against Embecta Corp.
Robbins LLP is urging Embecta Corp. (NASDAQ: EMBC) investors to contact the firm regarding a class action lawsuit filed against the company. The lawsuit alleges that Embecta Corp. misled investors about its business prospects, specifically regarding its fiscal year 2026 revenue guidance and pen needle segment strength. This follows a significant drop in Embecta's stock price by over 57% on May 5, 2026, after the company failed to meet its Q2 2026 guidance and lowered its full-year guidance by 46%, while also cutting its dividend by 93%.
EMBC CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds
Faruqi & Faruqi, LLP reminds investors of the August 17, 2026, deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against Embecta Corp. The lawsuit alleges Embecta made false and/or misleading statements regarding its guidance and pen needle business, leading to a significant stock price drop on May 5, 2026, after missing expectations. Investors who purchased Embecta securities between November 25, 2025, and May 4, 2026, are encouraged to contact the law firm to discuss their legal options.
EMBC CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Embecta Investors of Securities Class Action Lawsuit Deadline on August 17, 2026
Faruqi & Faruqi, LLP is investigating potential claims against Embecta Corp. (NASDAQ: EMBC) and reminds investors of the August 17, 2026 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit. The lawsuit alleges that Embecta made misleading statements regarding its financial guidance, particularly concerning its pen needle business, leading to a dramatic stock price decline of over 57.8% on May 5, 2026, after the company missed second-quarter expectations and lowered its fiscal year 2026 guidance. Investors who purchased Embecta securities between November 25, 2025, and May 4, 2026, may be eligible to participate.
EMBC SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Embecta Investors of Securities Class Action Lawsuit Deadline on August 17, 2026
Faruqi & Faruqi, LLP is reminding investors of the August 17, 2026, deadline to seek lead plaintiff status in a securities class action lawsuit against Embecta Corp. (NASDAQ: EMBC). The lawsuit alleges that Embecta made misleading statements regarding its financial performance and guidance, particularly concerning its pen needle business, which led to a significant stock price drop on May 5, 2026, after the company revised its fiscal year 2026 guidance. Investors who purchased Embecta securities between November 25, 2025, and May 4, 2026, and suffered losses are encouraged to contact Faruqi & Faruqi to discuss their legal options.
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Embecta Corp. Investors to Secure Counsel ...
The Rosen Law Firm is reminding investors who purchased Embecta Corp. (NASDAQ: EMBC) common stock between November 25, 2025, and May 4, 2026, of the August 17, 2026, lead plaintiff deadline. The firm is encouraging affected investors to secure counsel to potentially recover damages, alleging that Embecta made false or misleading statements regarding its financial results and guidance during the class period. Investors are advised to contact the Rosen Law Firm for more information on joining the class action.
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Embecta Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action – EMBC
Rosen Law Firm is reminding purchasers of Embecta Corp. (NASDAQ: EMBC) common stock between November 25, 2025, and May 4, 2026, of an important August 17, 2026 lead plaintiff deadline in a securities class action lawsuit. The lawsuit alleges that Embecta made false and misleading statements regarding its fiscal results and guidance, particularly concerning its pen needle business, leading to investor damages. Investors are encouraged to contact the firm to learn more and join the class action.
EMBC - Embecta Corp Latest SEC Filings
This article provides the latest SEC filings and comprehensive financial data for Embecta Corp (EMBC), a company specializing in healthcare medical instruments and supplies. It includes detailed information on market performance, valuation metrics, insider and institutional ownership, profitability, and short interest, alongside recent earnings release details.
Embecta Corp. (EMBC) Faces Securities Class Action for Allegedly Concealing Competitive Threats to Pen Needle Business -- HBSS
Embecta Corp. (NASDAQ: EMBC) is facing a securities class action lawsuit for allegedly misleading investors about competitive threats to its pen needle business between November 25, 2025, and May 4, 2026. The lawsuit follows a disastrous Q2 2026 earnings report where the company's adjusted EPS and pen needle revenues saw significant declines, leading to a substantial stock selloff and a 93% dividend reduction. Hagens Berman is investigating claims that Embecta's assurances of stability were misleading and encourages affected investors to come forward.
Beyond the Lawsuit: Embecta's Pen Needle Business Faces Structural Decline
Embecta's Q2 2026 earnings report revealed a significant decline in its pen needle business, triggering a class-action lawsuit alleging concealed competitive threats. Despite a growing overall market for pen needles, the company is struggling with commoditization, low-cost competitors, and the rise of alternative insulin delivery methods. The article concludes that Embecta appears to be a value trap due to its debt, negative book value, and ongoing credibility issues, advising extreme caution for investors.
Bronstein, Gewirtz & Grossman LLC Urges Embecta Corp. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Embecta Corp. (NASDAQ: EMBC) and its officers, alleging violations of federal securities laws. The lawsuit claims Embecta made materially false and misleading statements about its business, operations, and prospects, specifically regarding its pen needle business and unattainable guidance. Investors who purchased Embecta securities between November 25, 2025, and May 4, 2026, are encouraged to join the class action by August 17, 2026.
EMBC EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Embecta
Faruqi & Faruqi, LLP is reminding investors of Embecta (NASDAQ:EMBC) about a securities class action lawsuit deadline on August 17, 2026. The lawsuit alleges that Embecta made false and misleading statements regarding its financial results and guidance, particularly concerning its pen needle business, leading to a significant stock price drop. Investors who purchased Embecta securities between November 25, 2025, and May 4, 2026, are encouraged to contact the firm to discuss their legal rights.
EMBC Investors Have Opportunity to Lead Embecta Corp. Securities Fraud Lawsuit
The Rosen Law Firm is reminding investors who purchased common stock of Embecta Corp. (NASDAQ: EMBC) between November 25, 2025, and May 4, 2026, about the August 17, 2026 lead plaintiff deadline for a securities fraud lawsuit. The lawsuit alleges that Embecta made false and misleading statements about its financial results and that its guidance was unattainable, particularly regarding its pen needle business, which it touted as "incredibly resolute" shortly before missing expectations and cutting guidance. Investors who suffered damages are encouraged to join the class action.
EMBC Investors Have Opportunity to Lead Embecta Corp. Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm is reminding investors of a class action lawsuit against Embecta Corp. (NASDAQ: EMBC) for alleged securities fraud. The lawsuit claims that Embecta made misleading statements regarding its fiscal guidance for Q2 and full-year 2026, failing to disclose known headwinds in markets like the pen needle sector. Investors who purchased EMBC securities between November 25, 2025, and May 4, 2026, are encouraged to contact the firm by August 17, 2026, to discuss their rights.
EMBC INVESTOR DEADLINE: Embecta Corp. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit-- HBSS
Hagens Berman is encouraging Embecta Corp. investors who suffered substantial losses to come forward and lead a class action lawsuit. This follows a significant stock sell-off and analyst questioning after Embecta's Q2 2026 earnings report, where the company reported a sequential and year-over-year decline in adjusted EPS and pen needle revenues, and reduced its 2026 adjusted EPS guidance and dividend. The lawsuit alleges that Embecta's prior assurances about the stability and resilience of its insulin pen needle business were misleading.
EMBC STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Embecta Corp. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Embecta Corp. (NASDAQ:EMBC) on behalf of investors who purchased securities between November 25, 2025, and May 4, 2026. The lawsuit alleges that Embecta made materially false and misleading statements regarding its business and prospects, particularly concerning its pen needle segment, prior to lowering its fiscal year 2026 guidance. Investors who suffered losses have until August 17, 2026, to request to be appointed as lead plaintiff.
Embecta Corp. (EMBC) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
The Law Offices of Frank R. Cruz announced that shareholders of Embecta Corp. (EMBC) who experienced losses have an opportunity to participate as lead plaintiffs in a securities fraud class action lawsuit. The lawsuit alleges that Embecta's guidance was misleading, and that segment weakness, particularly in the U.S. pen needle market, negatively impacted revenue guidance and second-quarter 2026 results. Investors who suffered losses between November 25, 2025, and May 4, 2026, are encouraged to contact the firm before the August 17, 2026, lead plaintiff deadline.
EMBC SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Embecta Corp. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Embecta Corp. (NASDAQ:EMBC) on behalf of investors who purchased securities between November 25, 2025, and May 4, 2026. The lawsuit alleges that Embecta made misleading statements regarding its business and prospects, including its pen needle business, leading to missed guidance and a significant revenue decline. Investors with substantial losses are encouraged to join the lawsuit, and the deadline to request to be appointed as lead plaintiff is August 17, 2026.
ROSEN, A GLOBALLY RECOGNIZED FIRM, Encourages Embecta Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action – EMBC
The Rosen Law Firm is encouraging investors of Embecta Corp. (NASDAQ: EMBC) who purchased stock between November 25, 2025, and May 4, 2026, to secure legal counsel before an August 17, 2026 deadline. A class action lawsuit has been filed, alleging that Embecta made false and misleading statements about its fiscal results, particularly its pen needle business, leading to investor damages. The firm emphasizes its track record in securities class actions and invites affected investors to join the lawsuit.
EMBC Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Embecta Corp. Securities Lawsuit - Contact Levi & Korsinsky
Levi & Korsinsky, LLP has filed a securities class action lawsuit against Embecta Corp. (NASDAQ: EMBC) on behalf of investors who purchased shares between November 25, 2025, and May 4, 2026. The lawsuit alleges that Embecta made misleading statements regarding its fiscal year 2026 revenue and earnings guidance, which led to a significant stock price drop following the release of actual Q2 results. Investors who suffered losses are encouraged to contact Levi & Korsinsky to potentially lead the class action and recover their investments.
EMBECTA CORP. INVESTORS WITH LOSSES HAVE UNTIL AUGUST 17,
Bernstein Liebhard LLP reminds investors of Embecta Corp. (NASDAQ: EMBC) about the August 17, 2026 deadline to join a securities fraud class action lawsuit. The lawsuit alleges that Embecta made false statements about its business and financial stability between November 25, 2025, and May 4, 2026, leading to investor losses. Affected investors who bought or acquired Embecta common stock during this period are encouraged to contact the law firm.
Robbins LLP Urges EMBC Stockholders Who Lost Money Investing in Embecta Corp. to Contact the Firm for Information About Leading the Class Action
Robbins LLP has filed a class action lawsuit on behalf of Embecta Corp. (NASDAQ: EMBC) stockholders who purchased securities between November 25, 2025, and May 4, 2026. The firm alleges that Embecta Corp. misled investors by reaffirming continuous revenue guidance and strength in its pen needle segment, only to later report it failed to meet guidance and cut its dividend. The stock price subsequently fell over 57%, and stockholders are encouraged to contact Robbins LLP to serve as lead plaintiff by August 17, 2026.
EMBC Investors Have Opportunity to Lead Embecta Corp. Securities Fraud Lawsuit
The Rosen Law Firm announces a class action lawsuit on behalf of investors who purchased Embecta Corp. (NASDAQ: EMBC) common stock between November 25, 2025, and May 4, 2026. Investors who suffered losses allegedly due to misleading statements by Embecta regarding its fiscal results and guidance are encouraged to join the lawsuit and can seek to become lead plaintiff by August 17, 2026. The firm claims Embecta misrepresented its financial health, specifically its pen needle business, before cutting its 2026 fiscal guidance.
EMBC Faruqi & Faruqi, LLP Reminds Embecta Investors of Securities Class Action Lawsuit Deadline on August 17, 2026
Faruqi & Faruqi, LLP is reminding investors of Embecta Corp. (NASDAQ: EMBC) about the August 17, 2026 deadline to seek lead plaintiff status in a securities class action lawsuit. The lawsuit alleges that Embecta made misleading statements regarding its financial performance between November 25, 2025, and May 4, 2026, specifically concerning its fiscal results and initially portraying its pen needle business as "incredibly resolute" shortly before missing guidance and cutting its 2026 fiscal outlook, leading to a significant stock price drop. Investors who purchased Embecta securities during this period and suffered losses are encouraged to contact the firm to discuss their legal options.
Embecta Corp. (EMBC) Faces Securities Class Action for Allegedly Concealing Competitive Threats to Pen Needle Business -- HBSS
Embecta Corp. (EMBC) is facing a securities class action lawsuit for allegedly misleading investors about the stability and performance of its pen needle business between November 25, 2025, and May 4, 2026. The lawsuit follows a dismal Q2 2026 earnings report on May 5, 2026, where the company announced significant declines in adjusted EPS and pen needle revenues, contradicting previous assurances and leading to a sharp drop in stock price and a 93% dividend cut. Hagens Berman is investigating the claims that Embecta concealed competitive threats and revenue headwinds in this core business.
$EMBC Notification: Embecta Accused of Misrepresentations about its Insulin Pen Issues in Securities Fraud Class Action
Bleichmar Fonti & Auld LLP has filed a securities fraud class action lawsuit against Embecta Corp. and its executives. The lawsuit alleges that Embecta misled investors about the strength of its insulin pen needle product category, resulting in a significant stock drop after the company reported disappointing Q2 2026 results and reduced its dividend. Investors have until August 17, 2026, to seek appointment as lead plaintiff in the case.
EMBC Investors Have Opportunity to Lead Embecta Corp. Securities Fraud Lawsuit
The Rosen Law Firm is announcing a class action lawsuit on behalf of investors who purchased Embecta Corp. (NASDAQ: EMBC) common stock between November 25, 2025, and May 4, 2026. The lawsuit alleges that Embecta made false or misleading statements regarding its fiscal results and guidance, particularly concerning its pen needle business, leading to investor damages. Investors who wish to serve as lead plaintiff must do so by August 17, 2026.
Lost Money on Embecta Corp. (EMBC)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
Levi & Korsinsky, LLP has filed a class action lawsuit against Embecta Corp. (NASDAQ: EMBC) on behalf of investors who purchased securities between November 25, 2025, and May 4, 2026. The lawsuit alleges that Embecta made materially false and misleading statements, particularly regarding pen needle revenue, which led to a significant 57% drop in share value. Investors who suffered losses are encouraged to contact Levi & Korsinsky to learn about recovering damages, with a lead plaintiff deadline of August 17, 2026.
Lost Money on Embecta Corp. (EMBC)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
Levi & Korsinsky, LLP has filed a class action lawsuit against Embecta Corp. (NASDAQ: EMBC) on behalf of investors who purchased securities between November 25, 2025, and May 4, 2026. The lawsuit alleges that Embecta misrepresented its pen needle revenue guidance, causing shares to collapse by over 57% when the truth was revealed. Shareholders who suffered losses are encouraged to contact Levi & Korsinsky by the lead plaintiff deadline of August 17, 2026, to potentially recover damages.
Deadline Alert: Embecta Corp. (EMBC) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
Glancy Prongay Wolke & Rotter LLP is urging Embecta Corp. (EMBC) shareholders who suffered losses to contact them regarding a securities fraud lawsuit. The lawsuit alleges that Embecta made misleading statements and failed to disclose material adverse facts between November 25, 2025, and May 4, 2026, leading to a significant stock price drop after the company revealed a decline in revenue and lowered guidance. Investors have until August 17, 2026, to file a lead plaintiff motion.
Deadline Alert: Embecta Corp. (EMBC) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
Glancy Prongay Wolke & Rotter LLP is urging shareholders of Embecta Corp. (EMBC) who experienced losses to contact them regarding a securities fraud lawsuit. The lawsuit, with a lead plaintiff deadline of August 17, 2026, alleges that Embecta made misleading statements about its business operations and prospects. This follows a significant drop in Embecta's stock price after the company reported a revenue decline and lowered guidance for fiscal 2026.
Price to sales forward of Embecta Corp. – NASDAQ:EMBC
The article focuses on the "Price to sales forward" metric for Embecta Corp. (NASDAQ: EMBC). It appears to be a financial data snippet from TradingView, indicating no current trades and providing an overview of the company's financial information within the platform.
EMBC INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Embecta Investors of Securities Class Action Lawsuit Deadline on August 17, 2026
Faruqi & Faruqi, LLP is reminding investors of Embecta Corp. (NASDAQ: EMBC) about the August 17, 2026 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit. The lawsuit alleges that Embecta made false and misleading statements to investors between November 25, 2025, and May 4, 2026, regarding its fiscal results and guidance. This comes after the company reported a significant revenue decline and lowered its fiscal year 2026 guidance, leading to a dramatic drop in its stock price.
SG Americas Securities LLC Has $9.18 Million Position in Embecta Corp. $EMBC
SG Americas Securities LLC significantly increased its stake in Embecta Corp. by 138.4% in the first quarter, holding over 1 million shares valued at $9.18 million. Despite this, Wall Street sentiment on Embecta has soured, with several downgrades leading to a consensus "Strong Sell" rating and an average price target of $11.00. The company faces multiple securities class action lawsuits following weaker-than-expected Q2 results and a substantial stock price drop.
Class Action Lawsuit Filed Against Embecta Corp. (EMBC) - Recover Losses - Contact Levi & Korsinsky Before August 17, 2026
A class action lawsuit has been filed against Embecta Corp. (NASDAQ:EMBC) for alleged securities fraud between November 25, 2025, and May 4, 2026. The lawsuit claims Embecta made misleading statements about its financial performance, particularly its pen needle business, before dramatically missing expectations and lowering its fiscal year 2026 guidance. Investors who suffered losses on their Embecta securities are encouraged to contact Levi & Korsinsky, LLP before August 17, 2026, to explore potential recovery.
Deadline Alert: Embecta Corp. (EMBC) Shareholders Who Lost Money
Glancy Prongay Wolke & Rotter LLP reminds investors of an upcoming August 17, 2026 deadline to file a lead plaintiff motion in a class action lawsuit against Embecta Corp. (NASDAQ: EMBC). The lawsuit, filed on behalf of shareholders who suffered losses between November 25, 2025, and May 4, 2026, alleges that Embecta made misleading statements regarding its business, operations, and prospects, particularly concerning its revenue guidance and pen needle sales. This legal action follows a significant drop in Embecta's stock price after the company released disappointing Q2 fiscal 2026 financial results and lowered its guidance.
Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Embecta Corp. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. has filed a class action lawsuit against Embecta Corp. (NASDAQ: EMBC) on behalf of investors who purchased common stock between November 25, 2025, and May 4, 2026. The lawsuit alleges that Embecta made misleading statements regarding its fiscal results and guidance, particularly concerning its pen needle business, leading to a significant stock price drop. Investors have until August 17, 2026, to apply to be lead plaintiff.
Shareholders who lost money in shares of Embecta Corp. (NASDAQ: EMBC) Should Contact Wolf Haldenstein Immediately
Wolf Haldenstein Adler Freeman & Herz LLP has filed a securities fraud class action against Embecta Corp. (NASDAQ: EMBC) on behalf of investors who purchased shares between November 25, 2025, and May 4, 2026. The lawsuit alleges that Embecta made misleading positive statements while concealing financial issues, leading to a significant stock price drop after missing Q2 2026 guidance. Investors who suffered losses and wish to serve as lead plaintiff must file a motion by August 17, 2026.
Enterprise value to EBITDA forward of Embecta Corp. – NASDAQ:EMBC
This article from TradingView provides a financial snapshot of Embecta Corp. (NASDAQ: EMBC), specifically focusing on its enterprise value to EBITDA forward. The content indicates that the market was closed at the time of viewing, with no trades reported. The information presented appears to be a segment of a larger financial data platform, offering various financial metrics and stock analysis tools for users.
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Embecta Corp. of Class Action Lawsuit and Upcoming Deadlines - EMBC
Pomerantz LLP has announced a class action lawsuit against Embecta Corp. (NASDAQ: EMBC), urging investors who suffered losses to come forward by the August 17, 2026, lead plaintiff deadline. The lawsuit alleges securities fraud after Embecta missed its Q2 2026 financial guidance, lowered its full-year outlook, and reported a significant revenue decline and weakness in pen needle sales, leading to a nearly 58% drop in stock price. Investors can contact the firm for more information on joining the lawsuit.
Enterprise value to EBIT forward of Embecta Corp. – NASDAQ:EMBC
This article provides financial data on Embecta Corp. (NASDAQ: EMBC), specifically its enterprise value to forward EBIT. The content, presented as a data point within a financial platform, shows the "Period," "Value," and "Change %" for this metric. The article indicates that the market was closed at the time the data was presented.
Embecta Corp. (EMBC) Faces Securities Class Action for Allegedly Concealing Competitive Threats to Pen Needle Business – Hagens Berman
Embecta Corp. (EMBC) is facing a securities class action lawsuit filed by Hagens Berman on behalf of investors who purchased shares between November 25, 2025, and May 4, 2026. The lawsuit alleges that Embecta made misleading statements about the stability of its pen needle business, which constitutes over 70% of its revenue, leading to a significant stock selloff and analyst downgrades following a disastrous Q2 2026 earnings report. Hagens Berman is investigating whether Embecta management was transparent about competitive threats and revenue headwinds affecting its pen needle market.
Securities Lawsuit Alert: Embecta Corp. (EMBC) Investors - Contact Levi & Korsinsky Before August 17, 2026
Levi & Korsinsky, LLP has filed a securities class action lawsuit against Embecta Corp. (NASDAQ:EMBC) on behalf of investors who purchased securities between November 25, 2025, and May 4, 2026. The lawsuit alleges that Embecta made misleading statements regarding its financial performance, specifically its pen needle business, which led to a significant stock price drop of over 57.8% on May 5, 2026, after the company missed Q2 2026 guidance and lowered its fiscal year outlook. Investors who suffered losses are encouraged to contact the firm before August 17, 2026, to explore potential recovery.
Price to earnings forward of Embecta Corp. – NASDAQ:EMBC
This page provides financial information for Embecta Corp. (NASDAQ: EMBC), specifically focusing on its price-to-earnings forward ratio. The content, presented by TradingView, is primarily a data placeholder noting "No trades" and "No trades" with a copyright date of 2026.
EMBECTA CORP. (EMBC) INVESTOR ALERT Investors With Large
Bernstein Liebhard LLP has announced a securities class action lawsuit against Embecta Corp. (EMBC) on behalf of investors who purchased common stock between November 25, 2025, and May 4, 2026. The lawsuit alleges that Embecta made false and misleading statements about its business, growth, and financial stability, leading to artificially inflated stock prices and significant investor losses. Investors suffering large losses are encouraged to contact Bernstein Liebhard LLP to discuss their rights and the possibility of serving as a lead plaintiff.
EMBC Investors Have Opportunity to Lead Embecta Corp. Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm has announced a class action lawsuit against Embecta Corp. (NASDAQ: EMBC) for alleged securities fraud, encouraging investors who purchased securities between November 25, 2025, and May 4, 2026, to join. The lawsuit claims Embecta made false and misleading statements regarding its fiscal guidance, failing to disclose known market headwinds. Investors are urged to contact the firm before August 17, 2026, to discuss their rights.
EMBC UPCOMING DEADLINE: Levi & Korsinsky Alerts Embecta Corp. Stockholders of Securities Class Action - Contact the Firm
Levi & Korsinsky, LLP has alerted Embecta Corp. (NASDAQ: EMBC) stockholders about a pending securities class action lawsuit, with a deadline of August 17, 2026, for lead plaintiff appointment. The lawsuit alleges that Embecta's management concealed significant share loss in its pen needle segment at a single major customer and overall market volume softness, leading to a 57.8% stock collapse. Investors who purchased EMBC stock between November 25, 2025, and May 4, 2026, and suffered losses may be eligible to join.
Embecta Corp. (EMBC) Faces Securities Class Action for Allegedly Concealing Competitive Threats to Pen Needle Business -- HBSS
Hagens Berman has initiated a securities class action lawsuit against Embecta Corp. (EMBC) following a significant drop in its stock price after a Q2 2026 earnings report that contradicted previous assurances about its pen needle business. The lawsuit alleges that Embecta made misleading statements regarding the stability and resilience of its pen needle revenues, which constitute over 70% of its total revenue, despite knowing about market weaknesses. Investors suffered substantial losses when the company reported a massive decline in Q2 adjusted EPS and slashed its 2026 guidance, leading to a 93% cut in its dividend.
Embecta Corp. (EMBC) Faces Securities Class Action for Allegedly Concealing Competitive Threats to Pen Needle Business -- HBSS
Embecta Corp. (EMBC) is facing a securities class action lawsuit alleging that the company concealed competitive threats to its pen needle business, which constitutes over 70% of its total revenue. The lawsuit follows a disastrous Q2 2026 earnings report where Embecta's adjusted EPS and pen needle revenues declined significantly, leading to a massive stock selloff and a 93% dividend reduction. Hagens Berman is investigating claims that Embecta's assurances about the stability of its pen needle market were misleading, and investors who suffered substantial losses are encouraged to come forward.
Securities Class Action Lawsuit Filed Against Embecta Corp. (EMBC) - Levi & Korsinsky Represents Shareholders
Levi & Korsinsky, LLP has filed a securities class action lawsuit against Embecta Corp. (EMBC) on behalf of investors who suffered losses due to alleged securities fraud between November 25, 2025, and May 4, 2026. The lawsuit claims Embecta made materially false and misleading statements about its financial performance, particularly regarding its pen needle business, leading to a significant stock price drop after the company missed expectations and cut its 2026 fiscal guidance. Shareholders who purchased Embecta stock during this period are encouraged to learn about their rights to seek recovery.
